Finally, CDC6 emerged as the most promising target within FSS, as determined through analysis of 17 CRISPR/Cas9 cohorts, and its efficacy in pancreatic cancer (PC) was validated through experimental investigation. Here, CDC6 is linked to familial pancreatic carcinoma.